Clinical Trials Insight: 700029357
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2009
At a glance
- Drugs Caplacizumab (Primary)
- Indications Acute coronary syndromes; Embolism and thrombosis
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Sponsors Ablynx
- 22 Dec 2009 Results from the open label extension were reported in a Ablynx media release.
- 22 Dec 2009 Status changed from active, no longer recruiting to completed, according to a Ablynx media release.
- 01 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported in an Ablynx media release.